Search results
Showing 136 to 150 of 201 results for advanced breast cancer
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.
This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.
Endoscopic mastectomy and endoscopic wide local excision for breast cancer (HTG188)
Evidence-based recommendations on endoscopic mastectomy and endoscopic wide local excision for breast cancer. This involves removing part or all of the breast using special instruments inserted through small cuts in the skin (keyhole surgery).
View recommendations for HTG188Show all sections
Sections for HTG188
This guidance has been updated and replaced by NICE technology appraisal guidance 687.
This guidance has been updated and replaced by NICE technology appraisal guidance 836.
In development Reference number: GID-TA11588 Expected publication date: TBC
Image-guided radiofrequency excision biopsy of breast lesions (HTG198)
Evidence-based recommendations on image-guided radiofrequency excision biopsy of breast lesions. This involves inserting a probe that uses radiofrequency energy to cut through the breast internally, and removing the lump with a small area of surrounding tissue to test for cancer.
View recommendations for HTG198Show all sections
Sections for HTG198
Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)
Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 816.
Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.
Discontinued Reference number: GID-TA11318
Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)
This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.
Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
In development Reference number: GID-TA11771 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on the ATEC breast biopsy system